Notas do episódio
Welcome to the Red Leaf Securities podcast.
Today we’re joined by Dr Stuart Gunzburg, CSO and Executive Director of EVE Health Group. Stuart sits at the intersection of science, clinical development, and capital markets, helping guide EVE’s strategy as it targets large, patent-expiry pharmaceutical markets through reformulated therapies and telehealth-enabled distribution.
In this conversation, we explore the science and commercial pathway behind EVE’s lead products Libbo® and Dyspro™, the realities of clinical adoption in a competitive prescribing environment, and the regulatory and…
Site: spreaker.com

